32 results on '"Möbus V"'
Search Results
2. Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases
3. 160O Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC)
4. 86P Patients (pts) preference for different administration methods of trastuzumab (T) in pts with HER2+ early breast cancer (BC) treated within the GAIN-2 trial
5. Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study
6. Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry
7. Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial
8. Corrections to “Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression”
9. VinoMetro: Phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy
10. German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients
11. Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study
12. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial
13. Brain Metastases in Breast Cancer Network Germany (BMBC, GBG 79): Multicentric, retrospective and prospective collection of patient data and biomaterial from breast cancer patients as platform for translational research
14. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)
15. Gain2: Adjuvant Phase III Trial Comparing an Intensified Dose-Dense Adjuvant Therapy with Enpc Compared with a Dose-Dense, Dose-Adapted Therapy with Dtec Dtdocetaxel in Patients with Primary Breast Cancer and a High Risk of Recurrence
16. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
17. 4265 Pegfilgrastim on day 2 vs. day 4 within the prospective, multi- centered GAIN study: A phase III trial to compare ETC vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast cancer (GBG 33)
18. 0157 GAIN study: A phase III trial to compare ETC vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast cancer
19. 0148 REACT study: A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients
20. Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up
21. Muscarinic Receptors in Cell Lines from Ovarian Carcinoma: Negative Correlation with Survival of Patients
22. Treatment of patients with advanced ovarian cancer (FIGO IIb-IV) with cisplatin/paclitaxel or carboplatin/paclitaxel — An interim analysis of the ago study protocol ovar-3
23. Phase III trial comparing epirubicin/paclitaxel vs epirubicin/cyclophosphamid as first line treatment in metastatic breast cancer: Preliminary results of a German AGO trial
24. Prediction of axillary lymphatic node status in primary breast cancer — Comparison between positron emission tomography (PET) and sentinel-node biopsy
25. Estimation of Probability of Malignancy Using a Logistic Model Combining Physical Examination, Ultrasound, Serum CA 125, and Serum CA 72-4 in Postmenopausal Women with a Pelvic Mass: An International Multicenter Study
26. P92 Low morbidity and no mortality of high-dose cyclophosphamide, thiotepa and mitoxantrone plus autologous peripheral blood stem cell support for high-risk breast cancer patients
27. Cisplatin/paclitaxel vs carboplatin/paclitaxel: Optimizing of treatment in advanced ovarian cancer
28. Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer
29. Establishment and Characterization of Six New Human Endometrial Adenocarcinoma Cell Lines
30. Receptor binding of norgestimate — A new orally active synthetic progestational compound
31. Dihydrospirorenone (ZK30595): A novel synthetic progestagen-characterization of binding to different receptor proteins
32. Clinical significance of the tumor marker squamous-cell carcinoma antigen in diagnosis and follow-up of cervical cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.